These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24701712)

  • 1. [Disease modifying antirheumatic drugs].
    Luong Ba K; Gabay C
    Rev Med Suisse; 2014 Mar; 10(421):595-6, 598, 600-2. PubMed ID: 24701712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
    MacFarlane LA; Todd DJ
    Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are biologics more effective than classical disease-modifying antirheumatic drugs?
    Nurmohamed MT; Dijkmans BA
    Arthritis Res Ther; 2008; 10(5):118. PubMed ID: 18828888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.
    Pavelka K; Kavanaugh AF; Rubbert-Roth A; Ferraccioli G
    Rheumatology (Oxford); 2012 Jul; 51 Suppl 5():v12-21. PubMed ID: 22718922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapies in rheumatoid arthritis: a Latin American perspective.
    Burgos-Vargas R; Catoggio LJ; Galarza-Maldonado C; Ostojich K; Cardiel MH
    Reumatol Clin; 2013; 9(2):106-12. PubMed ID: 23337169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rheumatoid arthritis (updated Current Care guideline)].
    Hakala M; Hannonen P; Helve T; Korpela M; Mattila K; Möttönen T; Varis T;
    Duodecim; 2009; 125(19):2131-2. PubMed ID: 19938416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug management of early rheumatoid arthritis - 2008.
    Sokka T; Mäkinen H
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):93-102. PubMed ID: 19233049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P; Kingsley GH; Scott DL
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposal for a new nomenclature of disease-modifying antirheumatic drugs.
    Smolen JS; van der Heijde D; Machold KP; Aletaha D; Landewé R
    Ann Rheum Dis; 2014 Jan; 73(1):3-5. PubMed ID: 24072562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
    Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.
    Rantalaiho V; Kautiainen H; Virta L; Korpela M; Möttönen T; Puolakka K
    Scand J Rheumatol; 2011 Jan; 40(1):16-21. PubMed ID: 20726683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.